Non-invasive biomarkers in assisted reproductive technologies, current evidence, clinical utility and future perspectives - Takeaways - MDSpire

Non-invasive biomarkers in assisted reproductive technologies, current evidence, clinical utility and future perspectives

  • By

  • Athanasios Zikopoulos

  • Athanasia Sesse

  • Periklis Katopodis

  • Ariadni Theodora Katopodi

  • Vasilis Sebastian Paraschos

  • Maria Filiponi

  • Ioanna Bouba

  • Charilaos Kostoulas

  • Athanasios Zachariou

  • Ioannis Georgiou

  • July 2, 2026

  • 0 min

Share

  • 1

    Assisted reproductive technologies have advanced infertility treatment, but success rates are limited by inadequate assessment tools for reproductive potential.

  • 2

    Non-invasive biomarkers are critical for improving embryo selection and endometrial evaluation in in vitro fertilization and assisted reproductive technologies.

  • 3

    Current research focuses on embryo-derived follicular fluid and endometrial indicators, utilizing advanced imaging and profiling techniques.

  • 4

    Challenges in clinical translation of non-invasive biomarkers include methodological heterogeneity, limited validation, and standardization issues.

  • 5

    Integrative multi-parameter approaches are suggested to enhance predictive accuracy of non-invasive biomarkers in routine IVF practice.

Original Source(s)

Non-invasive biomarkers in assisted reproductive technologies, current evidence, clinical utility and future perspectives

  • by Athanasios Zikopoulos, Athanasia Sesse, Periklis Katopodis, Ariadni Theodora Katopodi, Vasilis Sebastian Paraschos, Maria Filiponi, Ioanna Bouba, Charilaos Kostoulas, Athanasios Zachariou, Ioannis Georgiou

  • July 2, 2026

Related Content

Trimester-specific gestational weight gain and adverse outcomes in GDM women: a retrospective cohort study

Development and application of a quality evaluation scale for ERAS health education in gynecologic malignancies

Alectinib combined with 5-aminolevulinic acid-based photodynamic therapy promotes apoptosis in endometrial cancer cells by targeting ferrochelatase